Nutraceuticals
News Releases
2016
December
Pharmaceuticals
Akebia Therapeutics and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.
Nutraceuticals
JSC High Performance Center Total Conditioning Research Project Joint research aims to promote sports medicine and science and boost international competitiveness (PDF: 190.3 KB)
Pharmaceuticals
Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Partnership with Nara Prefecture
Pharmaceuticals
FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder
November
Corporate
Otsuka Joins UN Global Compact (PDF: 170.8 KB)
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreements with Hokkaido Government Entities - Partnership Agreement for Promotion of Hokkaido Residents' Health Initiatives - - Cooperative Accord for Children's Education and Sports Promotion -
Corporate
Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors Asan Walking Festival in Itano
Pharmaceuticals
ICLUSIG® Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan
Nutraceuticals
Relationship between PMS/PMDD and production status of soy isoflavone metabolite equol Presentation to the Japan Society for Menopause and Women's Health
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Hyogo Prefecture
October
Nutraceuticals
Heatstroke Prevention Communication Project Hitosuzumi Awards 2016 Otsuka Pharmaceutical Named "Best Communicator" for Third Consecutive Year Proactive Efforts to Raise Awareness Also Recognized with "Top Runner Award"
Nutraceuticals
ORONAMIN C DRINK Recognized with Good Design Long Life Design Award
Nutraceuticals
POCARI SWEAT Recognized with Good Design Long Life Design Award
Pharmaceuticals
Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmaceuticals
Nutraceuticals
Otsuka Pharmaceutical Enters into Disaster Support Agreement with Fukui Prefecture
September
Pharmaceuticals
Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
Pharmaceuticals
Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder
Pharmaceuticals
ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.
Pharmaceuticals
Headline conclusions from the phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alzheimer's disease
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Yamanashi Prefecture
Pharmaceuticals
Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)
Pharmaceuticals
Otsuka and NEC agree to develop a smart medicine container to assist patients in taking daily anti-stroke medication at the appropriate time
Nutraceuticals
Otsuka Pharmaceutical Enters into Partnership Agreement with Yamagata Prefecture, Aiming to Achieve Japan's Top Healthy Life Expectancy
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Kanagawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Health Promotion Partnership with Kumamoto Prefecture
Pharmaceuticals
RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launches (PDF: 90.0 KB)
August
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Toyama Prefecture
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink Presents Awa Odori Sound Festival
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Miyagi Prefecture
Corporate
Notice of Completion of Transfer of Shares Held by Otsuka Pharmaceutical Co., Ltd.
July
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Shizuoka Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Gifu Prefecture
Pharmaceuticals
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdominal CT Scans, Launched in U.S. Developed by Otsuka Subsidiary Interpharma Praha
June
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Miyazaki Prefecture
Corporate
Otsuka Pharmaceutical Donates Funds for a Sub Rural Health Center in Myanmar For the stable provision of maternal and child health services
Pharmaceuticals
Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.
Corporate
Otsuka Pharmaceutical and IBM Japan to Set Up Joint Venture for Digital Health Solutions in Central Nervous System Field
Pharmaceuticals
VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION®pack (triple-drug blister packs containing TAKECAB® tablet) Now Available for Helicobacter pylori* Eradication in Japan
May
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership Agreement with Akita Prefecture
Nutraceuticals
Thirst-quenching support for optimum day-to-day condition Introducing New POCARI SWEAT Ion Water Powder (to make 750ml)
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Fukushima Prefecture
Pharmaceuticals
"Neupro® Patch", a Dopaminergic, Anti-Parkinsonian Drug,Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Nagasaki Prefecture
Corporate
Otsuka Pharmaceutical to Support Japan's COOL CHOICE Movement Cooperation in Public Awareness Campaigns to Encourage Wise Decisions to Counteract Global Warming
Corporate
Notice of Transfer of Shares Held by Otsuka Pharmaceutical Co., Ltd.
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Partnership Agreement with Osaka Prefecture
Nutraceuticals
Introducing Three New Flavors of Calorie Mate Jelly Focusing on the Need for a Nutritionally Balanced Jelly Beverage Option
April
Pharmaceuticals
FDA Issues Complete Response Letter For Digital Medicine New Drug Application
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Kagoshima Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Mie Prefecture
Pharmaceuticals
Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
Pharmaceuticals
Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Nutraceuticals
Otsuka Pharmaceutical Launches "POCARI SWEAT & TOKYO Project" in Cooperation with Tokyo Metropolitan Government
Nutraceuticals
New POCARI SWEAT Jelly for "Edible Hydration" First new form of POCARI SWEAT since initial launch 36 years ago
Nutraceuticals
Thirst-quenching beverage aims to help women maintain optimum day-to-day condition Renewed Version of POCARI SWEAT Ion Water
March
Nutraceuticals
Otsuka Pharmaceutical Signs Health Promotion Support Agreement with Hyogo Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Partnership with Hiroshima Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Disaster Relief Supply Agreement with Ishikawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Okayama Prefecture
Nutraceuticals
New casual soy bar with the pleasant crunchy texture of puffed soy "SOYJOY Crispy" Debuts in Three Flavors
Nutraceuticals
Otsuka Pharmaceutical Supports 37,000 Runners with Nutritional and Rehydration Products and Cadre of Blue Volunteers at Tokyo Marathon 2016
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors (PDF: 40.6 KB)
Pharmaceuticals
ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site
February
Pharmaceuticals
Anti-epileptic Drug E Keppra® (generic name: levetiracetam) Obtains Additional Indication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan
Pharmaceuticals
Takeda Obtains NDA Approval for Helicobacter pylori* Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP® pack 400", "VONOSAP® pack 800" and "VONOPION® pack" in Japan
Pharmaceuticals
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
Nutraceuticals
Otsuka Pharmaceutical Enters Partnership Agreement with Aomori Prefecture on Health Literacy* Enhancement
Nutraceuticals
Otsuka Pharmaceutical to Support Japan Anti-Doping Agency's Official Sports Pharmacist Certification System
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Health Promotion Partnership with Tokushima Prefecture
Pharmaceuticals
Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis
January
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Announces U.S. FDA Approval of ONZETRA™Xsail™ for the Acute Treatment of Migraine in Adults
Nutraceuticals
Otsuka Pharmaceutical Forms Joint Venture Company for Functional Food and Beverages in the Philippines
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Health Promotion Partnership with Iwate Prefecture
Pharmaceuticals